Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: A re-analysis of the Camarillo State Hospital data

Psychological Medicine

Volumn 27, Issue 2, 1997, Pages 261-268

  Wyatt, R J ^a   Green, M F ^b   Tuma, A H ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIOECONOMICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CALIFORNIA; CHLORPROMAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, STATE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0030942874     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291796004345     Document Type: Article

References (25)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders-III-R (3rd edn, Revised). American Psychiatric Press: Washington, DC.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders-IV (4th edn). American Psychiatric Press: Washington, DC.
3. Bartko, J. & Carpenter, W. (1976). On methods and theory of reliability. Journal of Nervous and Mental Disease 163, 307-317.
4. Carpenter, Jr., W. T., McGlashan, T. H. & Strauss, J. S. (1977). The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. American Journal of Psychiatry 134, 14-20.
5. Crow, T. J., Macmillan, J. F., Johnson, A. L. & Johnstone, E. C. (1986). A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 148, 120-127.
6. David, J. M. & Andrivkatis, S. (1986). The natural course of schizophrenia and effective maintenance drug treatment. Journal of Psychopharmacology 6 (Suppl), 2S-10S.
7. Davis, J. M. & Chang, S. S. (1978). A look at the data. In Controversy in Psychiatry (ed. J. P. Brady and H. K. H. Brodie), pp. 595-620. W. B. Saunders: Philadelphia.
8. Falloon, I. R. H. (1992). Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 55, 4-15.
9. Gilbert, P. L., Harris, M. J., McAdams, L. A. & Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry 52, 173-188.
10. Jeste, D. V. & Wyatt, R. J. (1982). Understanding and Treating Tardive Dyskinesia. Guilford Press: New York.
11. Lieberman, J., Jody, D., Geisler, S., Alvir, J., Loebel, A., Szymanski, S., Woerner, M. & Borenstein, M. (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 50, 369-376.
12. Loebel, A.D., Lieberman, J. A., Alvir, J. M., Mayerhoff, D.I., Geisler, S. H. & Szymanski, S. R. (1992). Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry 149, 1183-1188.
13. Kissling, W. (ed.) (1991). Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer: New York.
14. McEvoy, J. P., Schooler, N. R. & Wilson, W. H. (1991). Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin 27, 97-101.
15. May, P. R. A. (1968). Treatment of Schizophrenia. A Comparative Study of Five Treatment Methods. Science House: New York.
16. May, P. R. A., Tuma, A. H. & Dixon, W. J. (1976a). Schizophrenia: a follow-up study of results of treatment. I. Design and other problems. Archives of General Psychiatry 33, 474-478.
17. May, P. R. A., Tuma, A. H., Yale, C., Potepam, P. & Dixon, W. J. (1976b). Schizophrenia: a follow-up study of results of treatment. II. Hospital stay over two to five years. Archives of General Psychiatry 33, 481-486.
18. May, P. R. A., Tuma, A. H. & Dixon, W. J. (1981). Schizophrenia: a follow-up study of results of five forms of treatment. Archives of General Psychiatry 38, 776-784.
19. Miller, R. (1989). Schizophrenia as a progressive disorder: relations to EEG, CT, neuropathological and other evidence. Neurobiology 33, 17-43.
20. Post, R. M., Susan, R. & Weiss, B. (1992). Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 25, 41-43.
21. Tuma, A. H. & May, P. R. A. (1979). And if that doesn't work, what next...? A study of treatment failures in schizophrenia. Journal of Nervous and Mental Disease 167, 566-571.
22. Waddington, J. L., Youssef, H. A. & Kinsella, A. (1995). Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychological Medicine 25, 849-857.
23. Wyatt, R. J. (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 17, 325-351.
24. Wyatt, R. J. (1995a) Risks of withdrawing antipsychotic medications. Archives of General Psychiatry 52, 205-208.
25. Wyatt, R. J. (1995b). Antipsychotic medication and the long-term course of schizophrenia: therapeutic and theoretical implications. In Contemporary Issues in the Treatment of Schizophrenia (ed. C. Shriqui and H. Nasrallah), pp. 385-410. American Psychiatric Press: Washington, DC.